Autophagy mediates pharmacological lifespan extension by spermidine














































































































































Abstract:  Although  autophagy  has  widely  been  conceived  as  a  self‐destructive  mechanism  that  causes  cell  death,





stress.  These  beneficial  effects  are  lost  when  essential  autophagy  modulators  are  genetically  or  pharmacologically
inactivated,  indicating  that  autophagy  is  required  for  the  cytoprotective  and/or  anti‐aging  effects  of  spermidine  and
resveratrol. Genetic and functional studies indicate that spermidine inhibits histone acetylases, while resveratrol activates
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Autophagy (from the Greek, “auto” oneself, “phagy” to 
eat) involves the sequestration and degradation by 
lysosomal enzymes of old, supernumerary, damaged or 
ectopic organelles and/or portions of the cytoplasm [1]. 
At least three forms of autophagy have been described – 
macroautophagy, microautophagy, and chaperone-
mediated autophagy – that differ with respect to the 
mode of cargo delivery to lysosomes [2,3]. This article 
will focus on macroautophagy (herein referred to as 
autophagy), the most important catabolic pathway that 
cells employ for the turnover of long-lived proteins and 
organelles and also one of the most prominent 
cytoprotective mechanisms in eukaryotic cell biology 
[4].  
 
During macroautophagy, the cytoplasmic material 
targeted to degradation is delivered to lysosomes upon 
sequestration within double-membraned vesicles that 
are called autophagosomes. The generation of the 
autophagosome begins with the nucleation and 
elongation of the so-called phagophore, an isolation 
membrane that likewise originates from the 
endoplasmic reticulum. The edges of the phagophore 
then merge, resulting in the formation of a bona fide 
double-membraned autophagosome, which next fuses 
with a lysosome to generate an auto(phago)lysosome. 
Finally, the luminal content as well as the inner 
membrane of the auto(phago)lysosome (which together 
are known as “autophagic body”) are degraded by 
lysosomal hydrolases. The end products of these 
catabolic reactions are exported to the cytoplasm, where 
they can re-enter anabolic and/or bioenergetic 
metabolisms [2,3,5,6].  
 
The biochemical cascade that executes autophagy has 
originally been characterized at a molecular level in 
yeast (Saccharomyces cerevisiae) [7,8]. Hundreds of 
studies in different model organisms including 
mammals have confirmed that the essential machinery 
of autophagic sequestration and execution is phylo-
genetically conserved, and hence involves the orthologs 
of a series of yeast genes that have been 
designated  autophagy-related (ATG) genes [7,8]. 
Autophagy likewise occurs at low baseline levels in all 
cells to ensure the homeostatic turnover of long-lived 
proteins and organelles [4]. Moreover, autophagy is 
upregulated well beyond basal levels: (i) when cells 
need to mobilize intracellular nutrients, as occurring 
during glucose and/or amino acid deprivation, hypoxia 
or growth factor withdrawal [2,3]; and (ii) when cells 
rid themselves of potentially noxious cytoplasmic 
materials including damaged organelles, aggregates of 
misfolded proteins, or invading microbes [9,10].  
The complex regulation of autophagy in response to 
stress 
 
One of the key regulators of autophagy in human and 
murine cells is the mammalian target of rapamycin 
(mTOR, whose yeast ortholog is TOR) kinase, which 
suppresses autophagy in conditions of nutrient and 
growth factor repletion. Signal transducers including 
class I phoshatidylinositol-3-kinases (PI3Ks) and Akt 
link receptor tyrosine kinases to mTOR activation, 
thereby repressing autophagy in response to insulin, 
insulin-like growth factor (IGF) and other growth 
signals [11]. Activation of the mTOR complex 1 
(mTORC1) – and consequent repression of autophagy – 
can also be mediated by mitogen-activated protein 
kinases (MAPKs) including extracellular signal-
regulated kinases (ERKs) [12], by Ras-dependent 
activation of the p90 ribosomal S6 kinase [13], as well 
as by the Wnt signaling pathway [14]. Other prominent 
regulators of autophagy include (but are not limited to): 
AMP-activated protein kinase (AMPK), which inhibits 
mTOR in response to reduced ATP levels [15]; 
eukaryotic translation initiation factor 2α (eIF2α), 
which responds to nutrient deprivation as well as to 
double-stranded RNA (dsRNA) [16], ERN1 (whose 
yeast ortholog is known as IRE1), an endoplasmic 
reticulum (ER)-associated protein possessing intrinsic 
kinase and endoribonuclease activities and playing an 
important role in the alteration of gene expression upon 
ER stress [10,17]; and c-Jun N-terminal kinase (JNK), 
which is involved in multiple signaling cascades 
activated by stressful conditions [18].  
 
Our own work in this field has added to this list of 
autophagy regulators: members of the Bcl-2 protein 
family that contain a single Bcl-2 homology (BH) 
domain, the so-called BH3-only proteins, which 
displace (and hence derepress) the essential autophagy 
modulator Beclin 1 from inhibitory complexes with 
Bcl-2 or Bcl-XL [19,20]; Sirtuin 1, which responds to 
high NAD
+ levels, de facto acting as a sensor of nutrient 
availability [21]; the oncosuppressor protein p53, which 
inhibits autophagy when present in the cytoplasm [22]; 
the IκB kinase (IKK) complex, which is also essential 
for the activation of NF-κB by stress [23,24]; as well as 
the inositol 1,4,5-trisphosphate (IP3) receptor (IP3R) at 
the level of the ER [20,25]. Finally, autophagy is 
positively regulated by the transcription factor activity 
of E2F1 [26], FoxO3a [27,28], NF-κB [29] and p53 
[30,31], among others. The apical events of the 
phylogenetically ancient molecular pathway for 
autophagy involve ULK1 and ULK2 (the mammalian 
orthologs of Atg1) as well as Beclin 1 (the human 
ortholog of Atg6). Beclin 1 functions as an allosteric 
activator of the class III PI3K hVps34 (which promotes 
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phosphatidylinositol-3-phosphate), and is part of a highly 
dynamic multiprotein complex that can incorporate 
various autophagic stimulators (e.g., UVRAG, Bif-
1/endophilin B1, Ambra 1) and/or inhibitors (e.g., Bcl-2, 
RUBICON) [32-36].  
 
In synthesis, autophagy is connected to multiple stress 
pathways. In some cases, specific proteins and organelles 
are “tagged” for autophagic sequestration, implying that 
intrinsic features of the cargo determine its elimination 
by autophagy. This has been documented for 
proteotoxins [37-39], uncoupled mitochondria (a process 
that has been dubbed “mitophagy”) [40-42], peroxisomes 
(for which the term “pexophagy” has been introduced) 
[43]; damaged ER (which is eliminated by 
“reticulophagy”) [44]; and invading pathogens (which 
activate “xenophagy”) [45]. In many other instances, 
autophagy occurs in a rather unselective fashion and 
represents a general response of the cell that transits from 
baseline to induced, yet limited levels. It is tempting to 
speculate that this change from basal to upregulated 
autophagy may involve the activation of a general 
































ponsive and damage-sensing pathways. Complex 
molecular switches regulate the clear-cut separation 
between discrete cellular states including the transition 
from an undifferentiated to a more differentiated state, 
the advancement of the cell cycle, or the “decision” to 
activate the apoptotic cascade [46,47]. Usually, such 
switches integrate diverse signals that are transmitted 
through negative feedback loops (which maintain 
homeostasis and keep cells in a defined state) and 
positive feedback loops (which mark the rapid evolution 
between two states) [48]. There is abundant evidence that 
the induction of autophagy involves positive feedback 
loops. For example, we have documented (i) that 
autophagy induced by rapamycin (which inhibits mTOR) 
is accompanied by the degradation of p53 and the 
activation of IKK; (ii) that pharmacological inhibition of 
p53 with pifithrin-α leads to mTOR inhibition and IKK 
activation; and that (iii) transgene-enforced activation of 
IKK stimulates p53 degradation at the same time as it 
inhibits mTOR [22-24,49]. This implies that mTOR 
inhibition, IKK activation and the degradation of 
cytoplasmic p53 are cross-linked through a network of 
self-amplifying feedforward loops (Figure 1), although it 
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Cells that are stressed and on the verge of death 
frequently manifest the cytoplasmic accumulation of 
autophagosomes and auto(phago)lysosomes, an obser-
vation that has been (mis)interpreted as if autophagy 
would contribute to the cellular suicide [50]. Thus, 
hundreds of papers have described “autophagic” (also 
dubbed “type 2”) cell death, a cell demise subroutine 
preceded by massive autophagic vacuolization that is 
morphologically distinct from apoptosis (“type 1”) and 
necrosis (“type 3”) [51-54]. Although “autophagic cell 
death” undoubtedly exists as a morphological entity 
[53], this only exceptionally (at least in mammalian 
models) reflects the execution of cells by autophagy 
[50]. Rather, autophagy most frequently constitutes a 
(sometimes futile) mechanism of cellular adaptation to a 
diverse range of adverse conditions including 
hypoglycemia, hypoxia, lack of essential amino acids, 
absence of obligate growth factors or sublethal damage 
to cytoplasmic organelles including mitochondria and 
the ER [4,55,56]. Accordingly, the genetic inhibition of 
autophagy by knockout or knockdown of ATG  genes 
often precipitates the apoptotic or necrotic death of cells 
that otherwise would survive nutrient depletion, growth 
factor withdrawal, hypoxia, ionizing radiation or 
anticancer chemotherapy [11,50,57-60]. Deficient 
autophagy is directly involved in a number of 
pathologies including neurodegenerative diseases, heart 
failure, hereditary myopathies, steatosis/steatohepatitis 
and other chronic inflammatory states [6,61-64]. 
Genetic and pharmacological manipulations designed to 
induce autophagy have been shown to protect cells 
against otherwise lethal damage in vitro [5,6]. 
Autophagy favors the maintenance of high intracellular 
ATP levels [22,65], increases the capacity of cells to 
resist metabolic stress (hypoxia combined with nutrient 
deprivation) [22,66], prevents genomic instability 
[60,67] and limits the accumulation of potentially toxic 
proteins including proteotoxins that are responsible for 
neurodegeneration [10,38]. From a physiological point 
of view, aging can be viewed as a continuous decline in 
cellular and organismal functions that (at least partially) 
reflects the accumulation of misfolded proteins, 
oxidized lipids, as well as mutated mitochondrial and 
nuclear DNA.  
 
The sole regimen leading to lifespan extension in every 
organism tested to date is dietary restriction, a reduction 
of the organism's caloric intake not associated to 
malnutrition [68]. Dietary restriction is a potent inducer 
of autophagy in virtually all species including mammals 
[69-71]. In the nematode Caenorhabditis elegans, 
autophagy is required for lifespan prolongation 
mediated by caloric restriction [72-74] or p53 depletion 
[22,49,75-77]. Thus, worms undergoing dietary restrict-
tion do not live longer than control animals if 
concomitantly subjected to RNA interference (RNAi) 
against atg genes [72-74]. 
 
Rapamycin, which activates autophagy via inhibition of 
(m)TOR, has also been ascribed with prominent anti-
aging properties, in various model organisms. However, 
rapamycin cannot extend the chronological lifespan 
(i.e., the time post-mitotic cells survive during the 
stationary phase [78]) of yeast mutants that lack 
functional Atg1, Atg7 or Atg11 [79]. In C. elegans, the 
beneficial effects of rapamycin on longevity are lost 
when the essential autophagy modulator BEC-1 (the 
worm ortholog of mammalian Beclin 1 and yeast Atg6) 
is knocked down [74]. Thus, autophagy is required for 
rapamycin-mediated lifespan extension and delay of 
chronological aging in yeast and nematodes. Although it 
has not been formally demonstrated that rapamycin 
prolongs the lifespan of mice by inducing autophagy, 
even the treatment of pre-aged, genetically 
heterogeneous (out-bred) mice has been shown to 
increase longevity [80]. In mice, rapamycin avoids the 
age-related decline in hematopoietic stem cells function 
[81], an anti-senescence effect that has also been 
described in vitro [82,83]. 
 
Altogether, these results suggest that whole-body 
induction of autophagy by pharmacological agents may 
prolong the healthy lifespan, at least in laboratory 
conditions, supporting the idea that autophagy does not 
only confer cytoprotection but that it also has anti-aging 
effects at the organismal level. 
 
Autophagy mediates lifespan extension by 
resveratrol 
 
Driven by the aforementioned considerations, we 
launched the working hypothesis that autophagy 
constitutes (one of) the major mechanism(s) through 
which longevity-extending drugs operate. We thus 
studied whether resveratrol, a well-studied anti-aging 
agent [84],  would extend the lifespan of model 
organisms via the induction of autophagy. Although it 
also affects mitochondrial functions [85], resveratrol 
prominently acts as an allosteric activator of Sirtuin 1, a 
phylogenetically conserved deacetylase that senses the 
NAD
+/NADH ratio [84]. Resveratrol increases the 
longevity of yeast, nematodes, and flies (Drosophila 
melanogaster) and also exerts anti-aging effects on 
mice kept on a high-fat diet [84,86]. Circumstantial 
evidence indicates that resveratrol can induce autophagy 
in yeast (although this was attributed to the oxidation of 
mitochondrial lipids [87]) and in human cancer cells (in 
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cell death [88]). Sirtuin 1 is the first protein that has 
been demonstrated to prolong lifespan in yeast (and 
then in animals including C. elegans and flies) [89], and 
has also been shown to trigger autophagy in human and 
murine cultured cells [90].  
 
We confirmed that Sirtuin 1 overexpression increased 
the autophagic flux in human cancer cells in vitro, and 
that this effect was abolished by the addition of EX527, 
a pharmacological inhibitor of its catalytic activity 
[91,92]. Similarly, a transgene coding for SIR-2.1 (the 
C. elegans ortholog of human Sirtuin 1) caused 
autophagy in nematodes, suggesting that the link 
between Sirtuin 1 activation and autophagy is 
evolutionarily conserved [91,92]. Importantly, Sirtuin 1 
was required for the induction of autophagy by nutrient 
deprivation (that was achieved by culturing cells in the 
absence of serum, amino acids and glucose) but not by 
other stimuli. Thus, in human cells, the depletion (by 
RNAi) or inhibition (with EX527) of Sirtuin 1 fully 
prevented the pro-autophagic effects of nutrient 
starvation, yet failed to affect the stimulation of 
autophagy by mTOR inhibition (with rapamycin), p53 
inhibition (with pifithrin-α) or ER stress (triggered by 
the addition of tunicamycin). Similarly, loss-of-function 
mutations of sir-2.1  abolished autophagy induced by 
caloric restriction but not that promoted by rapamycin 
or tunicamycin in C. elegans [91,92]. Transgenic 
overexpression of sir-2.1  increased the median and 
maximum lifespan of nematodes as compared to non-
transgenic control strains with the same genetic 
background. This gain in longevity was lost when the 
essential autophagic modulator BEC-1 was depleted by 
RNAi [91,92]. RNAi-mediated knockdown of the C. 
elegans p53 ortholog CEP-1, a manipulation that 
extends longevity through the stimulation of autophagy 
[77], failed to further ameliorate the beneficial effects of 
sir-2.1  over-expression on longevity [91,92]. This 
epistatic analysis suggests that SIR-2.1 accumulation 
and CEP-1 depletion extend lifespan through a common 
final pathway that relies on the induction of autophagy. 
 
Another genetic intervention designed to indirectly 
activate Sirtuin 1 (or its worm ortholog SIR-2.1) 
consists in the transgenic overexpression of the gene 
coding for the pyrazinamidase/nicotinamidase PNC-1, 
which depletes nicotinamide, a negative regulator of 
Sirtuin 1/SIR-2.1. Transgenic overexpression of pnc-1 
did indeed induce autophagy in worms, and this 
response was abolished by RNAi-mediated depletion of 
SIR-2.1. Accordingly, the longevity-extending effects 
of PNC-1 were lost upon the knockdown of SIR-2.1, as 
well as upon that of either of the two essential 
autophagy modulators BEC-1 or ATG-5  [77]. Thus, 
both the overexpression and the metabolic activation of 
Sirtuin 1/SIR-2.1 increase lifespan through the 
induction of autophagy.  
 
Next, we investigated whether resveratrol would induce 
autophagy in C. elegans via the activation of SIR-2.1. 
Addition of resveratrol to the worm culture medium did 
indeed stimulate autophagy, and this effect was lost 
upon RNAi-mediated depletion of SIR-2.1. Similarly, 
resveratrol reduced the aging-associated mortality of C. 
elegans, unless the products of sir-2.1  or  bec-1  were 
knocked down [77]. We concluded from these 
experiments that resveratrol prolongs lifespan in human 
and nematode cells by inducing autophagy, which 
results from resveratrol-mediated activation of Sirtuin 
1/SIR-2.1 (rather than from an off-target effect). 
 
Autophagy mediates lifespan extension by 
spermidine 
 
Driven by the fact that the intracellular level of 
polyamines declines in (otherwise healthy) aging 
humans [93], we investigated whether the polyamine 
spermidine display anti-aging properties. To address 
this question, we first took advantage of a yeast strain 
that is deficient in the ornithine decarboxylase SPE1, 
which catalyzes the first step of polyamine biosynthesis. 
In chronological aging experiments, Δspe1 yeast cells 
exhibited an increased mortality (and hence a shortened 
lifespan), which could be restored to normal levels by 
supplementation with low doses (0.1 mM) of 
spermidine or its precursor putrescine [94]. 
Surprisingly, we found that higher concentrations of 
spermidine were able to increase the lifespan of wild 
type yeast cells with different genetic backgrounds. 
Thus, both chronological aging (which constitutes a 
model of post-mitotic aging) and replicative aging 
(which constitutes a model of stem cell aging) of yeast 
cells were significantly inhibited by spermidine 
supplementation. Lifespan prolongation in spermidine-
treated yeast cells could be correlated with the reduced 
acetylation of several lysine residues located at the N-
terminal tail of histone H3 (i.e., Lys9, Lys14 and 
Lys18) [94]. Deletion of sir2 (the yeast ortholog of 
Sirtuin 1) or any other sirtuin did not affect the ability 
of spermidine to extend chronological lifespan. Instead, 
epistatic analyses revealed that the anti-aging effect of 
spermidine was phenocopied by the knockout of histone 
acetylases, which hence were shown to regulate the 
same longevity-increasing pathway than spermidine 
does [94]. Moreover, spermidine efficiently inhibited 
general histone acetylase activity in extracts from 
purified yeast and mammalian nuclei in an in vitro 
assay [94]. These results suggest that spermidine acts 
differently from resveratrol. Thus, while the former 
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deacetylase activity of Sirtuin 1. However, formal 
evidence that the (de)acetylation of histones rather than 
that of other proteins (either in the nucleus or in the 
cytoplasm) account for the anti-aging properties of 
spermidine is still missing.  
 
Microarray profiling of spermidine-treated yeast cells 
revealed the transcriptional activation of several 
autophagy genes including atg7, atg11 and atg15, and 
we indeed found that spermidine induces autophagy in 
yeast cells. Similarly, spermidine was highly efficient in 
upregulating the autophagic pathways when it was 
added to the culture medium or solid food of C. elegans 
or D. melanogaster, respectively. The same concentra-
tions of spermidine that exerted pro-autophagic effects 
also had a marked lifespan-extending effect on yeast, 
nematodes and flies. The genetic inhibition of essential 
ATG genes (i.e., knockout of atg7 in yeast and flies, 
RNAi-mediated silencing of bec-1 in nematodes) 
abrogated longevity extension induced by spermidine, 
indicating this polyamine can prolong lifespan by the 




The aforementioned results indicate that resveratrol and 
spermidine can prolong the lifespan of model organisms 
through the induction of autophagy (Figure 2). In 
addition, our work raises at least three issues that must 
be addressed by future investigation. 
 
First, do resveratrol and spermidine extend longevity by 
acting on the same molecular pathway? While 
resveratrol can prolong lifespan through the activation 
of the deacetylase activity of Sirtuin 1 (or its non-
mammalian equivalents SIR2 in yeast and SIR-2.1 in C. 
elegans), spermidine inhibits the general histone 
acetylase activity of yeast and mouse liver extracts. 
Clearly, histone (de)acetylation has been recognized as 
an important epigenetic regulator of longevity [95,96]. 
However, a fraction of Sirtuin 1 is present in the 
cytoplasm, from where it can directly deacetylate 
essential autophagic proteins (including ATG5, ATG7 
and ATG8/LC3) [90], suggesting that (at least part of) 
the pro-autophagic effects of resveratrol derive from 
extranuclear, transcription-independent events. It will 
be important to know whether polyamines (like 
spermidine) and Sirtuin 1 activators (including 
resveratrol) can exert additive or synergistic effects on 
autophagy and longevity or whether these agents 
exactly activate the same molecular pathway. Moreover, 
the precise mechanisms by which spermidine and 


































spermidine  as  autophagy  inducers.  While  resveratrol
functions as an activator of the deacetylase Sirtuin 1, spermidine
inhibits  one  or  several  histone  acetylases.  Therefore,  both
resveratrol  and  spermidine  are  expected  to  favor  protein







exploration. Careful mechanistic and epistatic analyses 
are required to address this problem. 
 
Second, do all longevity-prolonging manipulations 
induce autophagy? And is autophagy required for all 
such intervention to extend lifespan? Current results 
clearly indicate that autophagy is indispensable for the 
anti-aging action of rapamycin, resveratrol and 
spermidine. Moreover, it has been suggested that 
autophagy is required for longevity extension by dietary 
restriction in C. elegans, although this has not been 
tested for all caloric restriction protocols [73]. It 
remains an ongoing conundrum whether an increased 
level of autophagy is required in C. elegans for 
longevity extension conferred by the deficiency of 
GTPase RHEB-1 [97], the transcription faction 
hypoxia-inducible factor 1 (HIF-1) [98] and its negative 
regulator VHL-1 [99], the ubiquitin ligase WWP-1 
[100], as well as the chaperones CCT4 and CCT6 [101]. 
A positive response to this question could establish a 
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here, which have mostly been obtained in simple model 
organisms and in laboratory conditions (where, for 
instance, the immunosuppressive side effects of 
resveratrol are certainly less incisive), be extrapolated to 
humans and to real life? Although rapamycin and 
polyamines can increase lifespan in mice [80,102], 
resveratrol only extends the longevity of mice that are 
kept on a high-caloric diet [86]. Clearly, rapamycin and 
resveratrol can induce autophagy in vivo, in mice 
[23,24,103]. However, it is thus far unknown whether 
there is indeed a cause-effect relationship between 
increased autophagy and healthy aging in mammals and 
in particular in humans. Such a causal relationship 
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